Healmusz Skin Tag Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab, ensuring that each wart is adequately covered. It is important to allow the application to dry completely.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition. The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, individuals with diabetes or poor blood circulation should not use this product, as these conditions may increase the risk of adverse effects.

Contact with the eyes must be avoided; in the event of exposure, the eyes should be flushed with water for 15 minutes.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin or any area that is infected or reddened. It should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought. Contact the Poison Control Center at 1-800-222-1222 without delay.

Healthcare professionals should advise patients to discontinue use and consult a physician if discomfort persists. Monitoring for any adverse reactions is recommended to ensure patient safety.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure safety and address any potential underlying issues that may arise during treatment.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Healmusz Skin Tag Remover (salicylic acid 17% skin tag remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no information available regarding the use of HEALMUSZ SKIN TAG REMOVER (salicylic acid 17% skin tag remover liquid) during pregnancy. The prescribing information does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in women who are pregnant or may become pregnant, as the potential risks to fetal outcomes are not established. It is advisable to weigh the benefits against any unknown risks before recommending this product to pregnant patients.

Lactation

There is no specific information available regarding the use of this medication in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the lack of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, altered mental status, or any unusual physiological responses.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution, monitor for symptoms, and provide appropriate supportive care in the event of an overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important for patients to understand the seriousness of this action and to act promptly.

Patients should be instructed to discontinue use and consult a doctor if they experience persistent discomfort after using the product. This guidance is crucial for ensuring patient safety and addressing any potential adverse effects.

Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes. In the event that the product comes into contact with the eyes, patients should be advised to flush the eyes with water for at least 15 minutes. It is essential to communicate that the product is non-edible and should be stored securely by capping it tightly and keeping it at room temperature, away from heat sources.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that the storage environment does not exceed excessive heat, defined as 37°C (99°F). Proper handling should be observed to maintain the integrity of the product throughout its shelf life.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes; in the event of exposure, the eye should be flushed with water for 15 minutes. Additionally, if the product is ingested, patients should seek medical assistance or contact the Poison Control Center immediately at 1-800-222-1222.

No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Healmusz Skin Tag Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)